10 research outputs found

    ΠŸΡ€ΠΎΡ„ΠΈΠ»Π°ΠΊΡ‚ΠΈΠΊΠ°, диагностика ΠΈ Π»Π΅Ρ‡Π΅Π½ΠΈΠ΅ тромбоэмболичСских ослоТнСний Π² Ρ‚Ρ€Π°Π²ΠΌΠ°Ρ‚ΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ ΠΎΡ€Ρ‚ΠΎΠΏΠ΅Π΄ΠΈΠΈ: мСтодичСскиС Ρ€Π΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°Ρ†ΠΈΠΈ

    Get PDF
    The guidelines describe modern approaches to the prevention, diagnosis, and treatment of thromboembolic complications in patients with injuries and after musculoskeletal surgery, in accordance with the interdisciplinary draft of the Clinical Guidelines (2022) Deep vein thrombosis of the extremities, which has passed public hearings and is being approved by the Russian Ministry of Health. The guidelines are designed for doctors of various specialties to provide medical care to specialized patients: orthopedic surgeons, anesthesiologists, resuscitators, clinical pharmacologists, health care organizers, medical students, residents, graduate students.Π’ мСтодичСских рСкомСндациях описаны соврСмСнныС ΠΏΠΎΠ΄Ρ…ΠΎΠ΄Ρ‹ ΠΊ ΠΏΡ€ΠΎΡ„ΠΈΠ»Π°ΠΊΡ‚ΠΈΠΊΠ΅, диагностикС ΠΈ Π»Π΅Ρ‡Π΅Π½ΠΈΡŽ тромбоэмболичСских ослоТнСний Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с Ρ‚Ρ€Π°Π²ΠΌΠ°ΠΌΠΈ ΠΈ опСрациями Π½Π° ΠΎΠΏΠΎΡ€Π½ΠΎ-Π΄Π²ΠΈΠ³Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΌ Π°ΠΏΠΏΠ°Ρ€Π°Ρ‚Π΅ Π² соотвСтствии с мСТдисциплинарным ΠΏΡ€ΠΎΠ΅ΠΊΡ‚ΠΎΠΌ клиничСских Ρ€Π΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°Ρ†ΠΈΠΉ 2022 Π³. Π’Ρ€ΠΎΠΌΠ±ΠΎΠ· Π³Π»ΡƒΠ±ΠΎΠΊΠΈΡ… Π²Π΅Π½ конСчностСй, ΠΏΡ€ΠΎΡˆΠ΅Π΄ΡˆΠΈΠΌ общСствСнныС ΡΠ»ΡƒΡˆΠ°Π½ΠΈΡ ΠΈ находящСмся Π½Π° ΡƒΡ‚Π²Π΅Ρ€ΠΆΠ΄Π΅Π½ΠΈΠΈ Π² ΠœΠΈΠ½Π·Π΄Ρ€Π°Π²Π΅ России. ΠœΠ΅Ρ‚ΠΎΠ΄ΠΈΡ‡Π΅ΡΠΊΠΈΠ΅ Ρ€Π΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°Ρ†ΠΈΠΈ рассчитаны Π½Π° Π²Ρ€Π°Ρ‡Π΅ΠΉ Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹Ρ… ΡΠΏΠ΅Ρ†ΠΈΠ°Π»ΡŒΠ½ΠΎΡΡ‚Π΅ΠΉ, ΠΎΠΊΠ°Π·Ρ‹Π²Π°ΡŽΡ‰ΠΈΡ… ΠΌΠ΅Π΄ΠΈΡ†ΠΈΠ½ΡΠΊΡƒΡŽ ΠΏΠΎΠΌΠΎΡ‰ΡŒ ΠΏΡ€ΠΎΡ„ΠΈΠ»ΡŒΠ½Ρ‹ΠΌ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Π°ΠΌ: Ρ‚Ρ€Π°Π²ΠΌΠ°Ρ‚ΠΎΠ»ΠΎΠ³ΠΎΠ²-ΠΎΡ€Ρ‚ΠΎΠΏΠ΅Π΄ΠΎΠ², Ρ…ΠΈΡ€ΡƒΡ€Π³ΠΎΠ², анСстСзиологов-Ρ€Π΅Π°Π½ΠΈΠΌΠ°Ρ‚ΠΎΠ»ΠΎΠ³ΠΎΠ², клиничСских Ρ„Π°Ρ€ΠΌΠ°ΠΊΠΎΠ»ΠΎΠ³ΠΎΠ², ΠΎΡ€Π³Π°Π½ΠΈΠ·Π°Ρ‚ΠΎΡ€ΠΎΠ² здравоохранСния, студСнтов мСдицинских Π²ΡƒΠ·ΠΎΠ², ΠΎΡ€Π΄ΠΈΠ½Π°Ρ‚ΠΎΡ€ΠΎΠ², аспирантов

    Observation Of Very High Energy Cosmic-ray Families In Emulsion Chambers At High Mountain Altitudes (i)

    Get PDF
    Characteristics of cosmic-ray hadronic interactions in the 1015 - 1017 eV range are studied by observing a total of 429 cosmic-ray families of visible energy greater than 100 TeV found in emulsion chamber experiments at high mountain altitudes, Chacaltaya (5200 m above sea level) and the Pamirs (4300 m above sea level). Extensive comparisons were made with simulated families based on models so far proposed, concentrating on the relation between the observed family flux and the behaviour of high-energy showers in the families, hadronic and electromagnetic components. It is concluded that there must be global change in characteristics of hadronic interactions at around 1016 eV deviating from thise known in the accelerator energy range, specially in the forwardmost angular region of the collision. A detailed study of a new shower phenomenon of small-pT particle emissions, pT being of the order of 10 MeV/c, is carried out and its relation to the origin of huge "halo" phenomena associated with extremely high energy families is discussed as one of the possibilities. General characteristics of such super-families are surveyed. Β© 1992.3702365431Borisov, (1981) Nucl. Phys., 191 BBaybrina, (1984) Trudy FIAN 154, p. 1. , [in Russian], Nauka, MoscowLattes, Hadronic interactions of high energy cosmic-ray observed by emulsion chambers (1980) Physics Reports, 65, p. 151Hasegawa, ICR-Report-151-87-5 (1987) presented at FNAL CDF Seminar, , Inst. for Cosmic Ray Research, Univ. of TokyoCHACALTAYA Emulsion Chamber Experiment (1971) Progress of Theoretical Physics Supplement, 47, p. 1Yamashita, Ohsawa, Chinellato, (1984) Proc. 3rd Int. Symp. on Cosmic Rays and Particle Physics, p. 30. , Tokyo, 1984, Inst. for Cosmic Ray Research, Univ. of Tokyo(1984) Proc. 3rd Int. Symp. on Cosmic Rays and Particle Physics, p. 1. , Tokyo, 1984Baradzei, (1984) Proc. 3rd Int. Symp. on Cosmic Rays and Particle Physics, p. 136. , Tokyo, 1984Yamashita, (1985) J. Phys. Soc. Jpn., 54, p. 529Bolisov, (1984) Proc. 3rd Int. Symp. on Cosmic rays and Particle Physics, p. 248. , Tokyo, 1984, Inst. for Cosmic Ray Research, Univ. of TokyoTamada, Tomaszewski, (1988) Proc. 5th Int. Symp. on Very High Energy Cosmic-Ray Interactions, p. 324. , Lodz, 1988, Inst. for Cosmic Ray Research, Univ. of Tokyo, PolandHasegawa, (1989) ICR-Report-197-89-14, , Inst. for Cosmic Ray Research, Univ. of TokyoCHACALTAYA Emulsion Chamber Experiment (1971) Progress of Theoretical Physics Supplement, 47, p. 1Okamoto, Shibata, (1987) Nucl. Instrum. Methods, 257 A, p. 155Zhdanov, (1980) FIAN preprint no. 45, , Lebedev Physical Institute, MoscowSemba, Gross Features of Nuclear Interactions around 1015eV through Observation of Gamma Ray Families (1983) Progress of Theoretical Physics Supplement, 76, p. 111Nikolsky, (1975) Izv. Akad. Nauk. USSR Ser. Fis., 39, p. 1160Burner, Energy spectra of cosmic rays above 1 TeV per nucleon (1990) The Astrophysical Journal, 349, p. 25Takahashi, (1990) 6th Int. Symp. on Very High Energy Cosmic-ray Interactions, , Tarbes, FranceRen, (1988) Phys. Rev., 38 D, p. 1404Alner, The UA5 high energy simulation program (1987) Nuclear Physics B, 291 B, p. 445Bozzo, Measurement of the proton-antiproton total and elastic cross sections at the CERN SPS collider (1984) Physics Letters B, 147 B, p. 392Wrotniak, (1985) Proc. 19th Cosmic-Ray Conf. La Jolla, 1985, 6, p. 56. , NASA Conference Publication, Washington, D.CWrotniak, (1985) Proc. 19th Cosmic-Ray Conf. La Jolla, 1985, 6, p. 328. , NASA Conference Publication, Washington, D.CMukhamedshin, (1984) Trudy FIAN, 154, p. 142. , Nauka, Moscow, [in Russian]Dunaevsky, Pluta, Slavatinsky, (1988) Proc. 5th Int. Symp. on Very High Energy Cosmic-Ray Interactions, p. 143. , Lodz, 1988, Inst. of Physics, Univ. of Lodz, PolandKaidalov, Ter-Martirosyan, (1987) Proc. 20th Int. Cosmic-Ray Conf., Moscow, 1987, 5, p. 141. , Nauka, MoscowShabelsky, (1985) preprints LNPI-1113Shabelsky, (1986) preprints LNPI-1224, , Leningrad [in Russian]Hillas, (1979) Proc. 16th Int. Cosmic-Ray Conf., Kyoto, 6, p. 13. , Inst. for Cosmic Ray Research, Univ. of TokyoBorisov, (1987) Phys. Lett., 190 B, p. 226Hasegawa, Tamada, (1990) 6th Int. Symp. on Very High Energy Cosmic-Ray Interactions, , Tarbes, FranceSemba, Gross Features of Nuclear Interactions around 1015eV through Observation of Gamma Ray Families (1983) Progress of Theoretical Physics Supplement, p. 111Ren, (1988) Phys. Rev., 38 D, p. 1404Dynaevsky, Zimin, (1988) Proc. 5th Int. Symp. on Very High Energy Cosmic-Ray Interaction, p. 93. , Lodz, 1988, Inst. of Physics, Univ. of Lodz, PolandDynaevsky, (1990) Proc. 6th Int. Symp. on Very High Energy Cosmic-Ray Interactions, , Tarbes, France(1989) FIAN preprint no. 208, , Lebedev Physical Institute, Moscow(1990) Proc. 21st Int. Cosmic-Ray Conf., Adelaide, 8, p. 259. , Dept. Physics and Mathematical Physics, Univ. of Adelaide, AustraliaHasegawa, (1990) ICR-Report-216-90-9, , Inst. for Cosmic-Ray Research, Univ. of TokyoTamada, (1990) Proc. 21st Int. Cosmic-Ray Conf., Adelaide, 1990, 8. , Dept. Physics and Mathematical Physics, Univ. of Adelaide, AustraliaTamada, (1990) ICR-Report-216-90-9(1981) Proc. 17th Int. Cosmic-Ray Conf., Paris, 5, p. 291(1990) Proc. Int. Cosmic-Ray Conf., Adelaide, 1990, 8, p. 267. , Dept. Physics and Mathematical Physics, Univ. of Adelaide, Australia(1989) Inst. Nucl. Phys. 89-67/144, , preprint, Inst. Nucl. Phys., Moscow State UnivSmilnova, (1988) Proc. 5th Int. Sym. on Very High Energy Cosmic-Ray Interactions, p. 42. , Lodz, 1988, Inst. of Physics, Univ. of Lodz, PolandGoulianos, (1986) Proc. Workshop of Particle Simulation at High Energies, , University of Wisconsin, Madison, USAIvanenko, (1983) Proc. 18th Int. Cosmic-Ray Conf., Bangalore, 1983, 5, p. 274. , Tata Inst. Fundamental Research, Bombay, IndiaIvanenko, (1984) Proc. Int. Symp. on Cosmic-Rays and Particle Physics, p. 101. , Tokyo, 1984, Inst. for Cosmic Ray Research, Univ. of Tokyo(1988) 5th Int. Symp. on Very High Energy Cosmic-Ray Interactions, p. 180. , Lodz, 1988, Inst. of Physics, Univ. of Lodz, Poland(1990) Proc. 21st Int. Cosmic-Ray Conf., Adelaide, 1990, 8, p. 251. , Dept. Physics and Mathematical Physics, Univ. of Adelaide, Australia(1991) Izv. AN USSR No. 4, , to be publishedNikolsky, Shaulov, Cherdyntseva, (1990) FIAN preprint no. 140, , Lebedev Physical Institute, Moscow, [in Russian](1987) Proc. 20th Int. Cosmic-Ray Conf., Moscow, 1987, 5, p. 326. , Nauka, Mosco

    A Study On Hadron-induced Shower Transition In Thick Lead Chambers

    No full text
    Three-dimensional development of cascade shower in lead initiated by high energy proton-Pb and pion-Pb interactions are calculated by full Monte-Carlo simulation assuming simple geometrical model for hadron-nucleus interactions. It is shown that fluctuations in shower development is very large but the extraordinary long penetrating showers observed in the Pamir thick lead chamber experiment can not be explained by simple fluctuations of shower development initiated by ordinary hadron-Pb interactions.523222224Baradzei, L.T., (1992) Nucl. Phys., B370, p. 365Lattes, C.M.G., Fujimoto, Y., Hasegawa, S., (1981) Phys. Rep., 65, p. 151Arisawa, T., (1994) Nucl. Phys., B424, p. 241Tamada, M., (1995) J.Phys. G: Nucl.Part.Phys., 21, p. 1387Alner, G.L., (1987) Nucl.Phys., B291, p. 445Okamoto, M., Shibata, T., (1987) Nucl. Instr. and Meth., A257, p. 15

    РСгуляторы Π°Π½Π³ΠΈΠΎΠ³Π΅Π½Π΅Π·Π° ΠΏΡ€ΠΈ Ρ…ΠΈΠΌΠΈΠΎΠΈΠ½Π΄ΡƒΡ†ΠΈΡ€ΠΎΠ²Π°Π½Π½ΠΎΠΉ пСрифСричСской ΠΏΠΎΠ»ΠΈΠ½Π΅ΠΉΡ€ΠΎΠΏΠ°Ρ‚ΠΈΠΈ

    No full text
    Background: Chemotherapy-induced peripheral polyneuropathy is a major neurotoxicity of treatment for acute lymphoblastic leukemia (ALL) in children. Pathophysiological mechanisms of the injury of peripheral neural system are not fully investigated; however, some studies have shown the involvement of vascular endothelial growth factors. Aim: To evaluate plasma levels of angiogenic growth factors in children with ALL and to identify their association with the development of vincristine-induced peripheral polyneuropathy. Materials and methods: This single center prospective study included 41 patients with ALL aged 3 to 17 years. All patients were given the ALL-MB 2015 chemotherapy regimen. Depending on the vincristine-induced peripheral polyneuropathy, the patients were divided into two groups: the main group (n = 22) comprised of the patients with neurological signs and symptoms of peripheral neuropathy and the control group (n = 19), those without clinical signs of the peripheral nervous system involvement. The levels of angiogenic growth factors (VEGF-A, VEGF-D, PlGF-1, and PDGF-BB) were measured in plasma by multiparameter immunofluorescent analysis. Results: During 3 months of the follow up the chemotherapy-induced signs of peripheral polyneuropathy developed in 53.6% (n = 22) of the children. In 72.7% (n = 16) of the patients the chemotherapy-induced peripheral polyneuropathy was characterized by a combination of neurologic abnormalities with prevailing motor symptoms. The comparative analysis of plasma angiogenic growth factors in children with ALL depending on the presence or absence of the vincristine-induced peripheral polyneuropathy showed that there was a significant decrease of the VEGF-A in those with chemotherapy-induced peripheral polyneuropathy, compared to those without (Me [Q1; Q3]: 178.20 [138.40; 228.45] and 558.50 [160.10; 650.0], respectively, p 0.017). This parameter had diagnostic sensitivity of 77.7% and specificity of 76.9%. Conclusion: We have shown a high clinical value of plasma vascular endothelial growth factor (VEGF-A) level, which makes it possible to consider it as a significant biological marker of neurotoxicity in vincristine-induced peripheral polyneuropathy.ОбоснованиС. Π₯имиоиндуцированная пСрифСричСская полинСйропатия относится ΠΊ основным нСйротоксичСским ослоТнСниям ΠΏΡ€ΠΈ Π»Π΅Ρ‡Π΅Π½ΠΈΠΈ острого лимфобластного Π»Π΅ΠΉΠΊΠΎΠ·Π° (ΠžΠ›Π›) Ρƒ Π΄Π΅Ρ‚Π΅ΠΉ. ΠŸΠ°Ρ‚ΠΎΠ³Π΅Π½Π΅Ρ‚ΠΈΡ‡Π΅ΡΠΊΠΈΠ΅ ΠΌΠ΅Ρ…Π°Π½ΠΈΠ·ΠΌΡ‹ поврСТдСния пСрифСричСской Π½Π΅Ρ€Π²Π½ΠΎΠΉ систСмы Π΄ΠΎ ΠΊΠΎΠ½Ρ†Π° Π½Π΅ ΠΈΠ·ΡƒΡ‡Π΅Π½Ρ‹, ΠΎΠ΄Π½Π°ΠΊΠΎ исслСдования ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΈ участиС Ρ„Π°ΠΊΡ‚ΠΎΡ€ΠΎΠ² роста эндотСлия сосудов. ЦСль ΠΎΡ†Π΅Π½ΠΈΡ‚ΡŒ содСрТаниС уровня Π°Π½Π³ΠΈΠΎΠ³Π΅Π½Π½Ρ‹Ρ… Ρ„Π°ΠΊΡ‚ΠΎΡ€ΠΎΠ² роста Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡ€ΠΎΠ²ΠΈ Ρƒ Π΄Π΅Ρ‚Π΅ΠΉ ΠΏΡ€ΠΈ ΠžΠ›Π› ΠΈ ΠΎΠΏΡ€Π΅Π΄Π΅Π»ΠΈΡ‚ΡŒ ΠΈΡ… связь с Ρ„ΠΎΡ€ΠΌΠΈΡ€ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ пСрифСричСской ΠΏΠΎΠ»ΠΈΠ½Π΅ΠΉΡ€ΠΎΠΏΠ°Ρ‚ΠΈΠΈ, ΠΈΠ½Π΄ΡƒΡ†ΠΈΡ€ΠΎΠ²Π°Π½Π½ΠΎΠΉ винкристином. ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π» ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. Π’ ΠΎΠ΄Π½ΠΎΡ†Π΅Π½Ρ‚Ρ€ΠΎΠ²ΠΎΠΌ проспСктивном исслСдовании участвовал 41 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ Π² возрастС ΠΎΡ‚ 3 Π΄ΠΎ 17 Π»Π΅Ρ‚ с ΠžΠ›Π›. ВсС ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Ρ‹ ΠΏΠΎΠ»ΡƒΡ‡Π°Π»ΠΈ Ρ…ΠΈΠΌΠΈΠΎΡ‚Π΅Ρ€Π°ΠΏΠΈΡŽ ΠΏΠΎ ΠΏΡ€ΠΎΡ‚ΠΎΠΊΠΎΠ»Ρƒ ALL-MB 2015. Π’ зависимости ΠΎΡ‚ развития пСрифСричСской ΠΏΠΎΠ»ΠΈΠ½Π΅ΠΉΡ€ΠΎΠΏΠ°Ρ‚ΠΈΠΈ, ΠΈΠ½Π΄ΡƒΡ†ΠΈΡ€ΠΎΠ²Π°Π½Π½ΠΎΠΉ винкристином, ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Ρ‹ Π±Ρ‹Π»ΠΈ Ρ€Π°Π·Π΄Π΅Π»Π΅Π½Ρ‹ Π½Π° Π΄Π²Π΅ Π³Ρ€ΡƒΠΏΠΏΡ‹: Π² ΠΎΡΠ½ΠΎΠ²Π½ΡƒΡŽ (n = 22) вошли Π±ΠΎΠ»ΡŒΠ½Ρ‹Π΅, ΠΈΠΌΠ΅ΡŽΡ‰ΠΈΠ΅ нСврологичСскиС ΠΏΡ€ΠΈΠ·Π½Π°ΠΊΠΈ пСрифСричСской ΠΏΠΎΠ»ΠΈΠ½Π΅ΠΉΡ€ΠΎΠΏΠ°Ρ‚ΠΈΠΈ, Π² Π³Ρ€ΡƒΠΏΠΏΡƒ сравнСния (n = 19) Π΄Π΅Ρ‚ΠΈ Π±Π΅Π· клиничСских симптомов пораТСния пСрифСричСской Π½Π΅Ρ€Π²Π½ΠΎΠΉ систСмы. ΠœΠ΅Ρ‚ΠΎΠ΄ΠΎΠΌ ΠΌΡƒΠ»ΡŒΡ‚ΠΈΠΏΠ°Ρ€Π°ΠΌΠ΅Ρ‚Ρ€ΠΈΡ‡Π΅ΡΠΊΠΎΠ³ΠΎ иммунофлуорСсцСнтного Π°Π½Π°Π»ΠΈΠ·Π° Π² ΠΏΠ»Π°Π·ΠΌΠ΅ ΠΊΡ€ΠΎΠ²ΠΈ опрСдСляли ΡƒΡ€ΠΎΠ²Π΅Π½ΡŒ Π°Π½Π³ΠΈΠΎΠ³Π΅Π½Π½Ρ‹Ρ… Ρ„Π°ΠΊΡ‚ΠΎΡ€ΠΎΠ² роста (VEGF-A, VEGF-D, PlGF-1, PDGF-BB). Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. Π’ Ρ‚Π΅Ρ‡Π΅Π½ΠΈΠ΅ 3-мСсячного ΠΏΠ΅Ρ€ΠΈΠΎΠ΄Π° наблюдСния ΠΏΡ€ΠΈΠ·Π½Π°ΠΊΠΈ пСрифСричСской ΠΏΠΎΠ»ΠΈΠ½Π΅ΠΉΡ€ΠΎΠΏΠ°Ρ‚ΠΈΠΈ Π½Π° Ρ„ΠΎΠ½Π΅ Ρ…ΠΈΠΌΠΈΠΎΡ‚Π΅Ρ€Π°ΠΏΠΈΠΈ появились Ρƒ 53,6% (n = 22) Π΄Π΅Ρ‚Π΅ΠΉ. ΠŸΡ€ΠΈ этом Ρƒ 72,7% (n = 16) Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… химиоиндуцированная пСрифСричСская полинСйропатия Ρ…Π°Ρ€Π°ΠΊΡ‚Π΅Ρ€ΠΈΠ·ΠΎΠ²Π°Π»Π°ΡΡŒ сочСтаниСм нСврологичСских Π½Π°Ρ€ΡƒΡˆΠ΅Π½ΠΈΠΉ с ΠΏΡ€Π΅ΠΎΠ±Π»Π°Π΄Π°Π½ΠΈΠ΅ΠΌ ΠΌΠΎΡ‚ΠΎΡ€Π½Ρ‹Ρ… симптомов. Π‘Ρ€Π°Π²Π½ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹ΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΏΠ»Π°Π·ΠΌΠ΅Π½Π½Ρ‹Ρ… Π°Π½Π³ΠΈΠΎΠ³Π΅Π½Π½Ρ‹Ρ… Ρ„Π°ΠΊΡ‚ΠΎΡ€ΠΎΠ² роста Π² Π³Ρ€ΡƒΠΏΠΏΠ°Ρ… Π΄Π΅Ρ‚Π΅ΠΉ с ΠžΠ›Π› Π² зависимости ΠΎΡ‚ формирования пСрифСричСской ΠΏΠΎΠ»ΠΈΠ½Π΅ΠΉΡ€ΠΎΠΏΠ°Ρ‚ΠΈΠΈ, ΠΈΠ½Π΄ΡƒΡ†ΠΈΡ€ΠΎΠ²Π°Π½Π½ΠΎΠΉ винкристином, ΠΏΠΎΠΊΠ°Π·Π°Π», Ρ‡Ρ‚ΠΎ Ρƒ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… с Ρ…ΠΈΠΌΠΈΠΎΠΈΠ½Π΄ΡƒΡ†ΠΈΡ€ΠΎΠ²Π°Π½Π½ΠΎΠΉ пСрифСричСской ΠΏΠΎΠ»ΠΈΠ½Π΅ΠΉΡ€ΠΎΠΏΠ°Ρ‚ΠΈΠ΅ΠΉ Π² ΠΎΡ‚Π»ΠΈΡ‡ΠΈΠ΅ ΠΎΡ‚ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ², Π½Π΅ ΠΈΠΌΠ΅ΡŽΡ‰ΠΈΡ… Π΄Π°Π½Π½Ρ‹Ρ… Π·Π° ΠΏΠΎΡ€Π°ΠΆΠ΅Π½ΠΈΠ΅ пСрифСричСской Π½Π΅Ρ€Π²Π½ΠΎΠΉ систСмы, установлСно статистичСски Π·Π½Π°Ρ‡ΠΈΠΌΠΎΠ΅ сниТСниС Ρ„Π°ΠΊΡ‚ΠΎΡ€Π° роста эндотСлия сосудов А (Me [Q1; Q3]: 178,20 [138,40; 228,45] ΠΈ 558,50 [160,10; 650,0] соотвСтствСнно, p 0,017). ΠŸΡ€ΠΈ ΠΎΡ†Π΅Π½ΠΊΠ΅ клиничСской цСнности Π΄Π°Π½Π½ΠΎΠ³ΠΎ ΠΏΠ°Ρ€Π°ΠΌΠ΅Ρ‚Ρ€Π° диагностичСская Ρ‡ΡƒΠ²ΡΡ‚Π²ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΡŒ составила 77,7%, Π° ΡΠΏΠ΅Ρ†ΠΈΡ„ΠΈΡ‡Π½ΠΎΡΡ‚ΡŒ 76,9%. Π—Π°ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅. Нами ΠΏΠΎΠΊΠ°Π·Π°Π½Π° высокая клиничСская Ρ†Π΅Π½Π½ΠΎΡΡ‚ΡŒ ΠΏΠ»Π°Π·ΠΌΠ΅Π½Π½ΠΎΠ³ΠΎ Ρ„Π°ΠΊΡ‚ΠΎΡ€Π° роста эндотСлия сосудов (VEGF-A), Ρ‡Ρ‚ΠΎ позволяСт Ρ€Π°ΡΡΠΌΠ°Ρ‚Ρ€ΠΈΠ²Π°Ρ‚ΡŒ Π΅Π³ΠΎ ΠΊΠ°ΠΊ Π·Π½Π°Ρ‡ΠΈΠΌΡ‹ΠΉ биологичСский ΠΌΠ°Ρ€ΠΊΠ΅Ρ€ нСйротоксичности ΠΏΡ€ΠΈ пСрифСричСской ΠΏΠΎΠ»ΠΈΠ½Π΅ΠΉΡ€ΠΎΠΏΠ°Ρ‚ΠΈΠΈ, Π²Ρ‹Π·Π²Π°Π½Π½ΠΎΠΉ винкристином
    corecore